(RTTNews) - Ascendis Pharma A/S (ASND) said that it has commenced an underwritten public offering of $300 million of American Depositary Shares or "ADSs", each of which represents one ordinary share of Ascendis.
In addition, the company said it expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the public offering price, less the underwriting commissions.
The offering is subject to market and other conditions.
J.P. Morgan, Morgan Stanley, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the proposed offering.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
